These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test.
    Author: Stewart WC, Stewart JA, Crockett S, Kubilus C, Brown A, Shams N.
    Journal: Acta Ophthalmol Scand; 2002 Jun; 80(3):272-6. PubMed ID: 12059865.
    Abstract:
    PURPOSE: To compare the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test. METHODS: Thirty subjects aged 18-37 years (mean age = 24.1 years) were randomized to one of six treatment sequences in a three-treatment, three-period crossover study (William's design). Study medication was instilled b.i.d. for 5 days before visits 2, 3, and 4. Between treatments, study medication was washed out for 9-10 days. Each subject underwent a submaximal treadmill test at visits 2 through 4, 15 min after dosing. RESULTS: After 15 min of exercise, average heart rates were 143.1 +/- 21.2, 134.5 +/- 20.0 and 145.4 +/- 20.8 bpm for the unoprostone, timolol and placebo treatments, respectively. At no timepoint was there a statistically significant difference between the unoprostone and placebo treatments (p > 0.05). Beginning with the second minute of exercise, timolol produced a greater decrease in heart rate at all timepoints from placebo than unoprostone (p < 0.05). No consistent differences in systolic or diastolic blood pressure were observed between drug treatments (p > 0.05). CONCLUSIONS: Unlike timolol, unoprostone 0.15% does not reduce exercise-induced heart rate, indicating a lack of clinical effect on systemic beta-adrenergic receptors in young and healthy subjects.
    [Abstract] [Full Text] [Related] [New Search]